Clinical Trial Update: Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction [Phase 1]

View source ↗

Summary

Phase 1 trial of Vandetanib combined with Oxaliplatin and Docetaxel in advanced cancer of the esophagus or gastroesophageal junction has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Gastroesophageal Junction
• Esophageal Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• OXALIPLATIN (Oxaliplatin)
• Vandetanib (vandetanib)

Snippet

Sponsor: Case Comprehensive Cancer Center | Conditions: Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer | Phase 1 | Status: TERMINATED